Actively Recruiting

Age: 0 - 18Years
All Genders
ID04252989

Atropine 0.01% Eyedrops for Evolutive Myopia Treatment in Children MYOPSTOP

Led by Centre Hospitalier Universitaire de Saint Etienne · Updated on 2025-03-18

50

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Myopia, especially among children and adolescents, is increasing worldwide and has reached epidemic levels in some Asian regions. Researchers are focusing on evaluating the use of atropine 0.01% eye drops as a treatment for progressive myopia in children. This observational study aims to build a database to share results and clinical experience, particularly within the French population where published data are limited. Participants in this study are children with active myopia who are treated daily with atropine 0.01% eye drops. The study involves collecting detailed ophthalmological and demographic data at regular intervals. These include measurements such as refractions, intra-ocular pressure, dilated eye exams, and biometry, all assessed every six months until participants reach 18 years of age. Throughout the study, participants will undergo comprehensive eye examinations and monitoring every six months to track changes and potential side effects like halos or photophobia. Researchers will gather data on treatment adherence and any undesirable events. The study spans from the initial treatment phase through to age 18, providing long-term observation of the treatment's impact and safety.

CONDITIONS

Brief Title

Atropine 0.01% Eyedrops for Evolutive Myopia Treatment in Children

Who Can Participate

Age: 0 - 18Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Children with active myopia treated with ATROPINE 0.01% eye drops
  • Patient affiliated with a social security organization
  • Agreement of both parents
Not Eligible

You will not qualify if you...

  • Non compliance with treatment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Long-term Monitoring

Duration - Every 6 months up to age 18 years

Participants are observed over time with regular eye examinations and data collection related to their myopia treatment and eye health.

Visits every 6 months

Trial Site Locations

Total: 1 location

1

CHU de Saint Etienne

Saint-Etienne, France, 42055

Actively Recruiting

Loading map...

Research Team

M

Marie Caroline TRONE

M

Marie PEURIERE

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here